en.aazsante.fr

The Largest Portal Of Health And Quality Of Life.

FDA approves medicine that can treat different types of cancer

FDA approves medicine that can treat different types of cancer

Last week, the Food and Drug Administration ), has granted approval for a cancer drug that takes into account the molecular feature of the tumor rather than where the cancer is located.

The name of the substance is Pembrolizumab, and is indicated for the treatment of adult and pediatric patients with tumors that have not responded to conventional treatment and exhibit microsatellite instability. In other words, tumors that contain within them an abnormality that affects the correct repair of the DNA inside the cell.

According to the FDA, approximately 5% of patients are identified with this type of biomarker. This indication is intended for patients with solid tumors who have progressed after treatment and who do not have satisfactory alternative therapeutic options. Treatment with Pembrolizumab could be more effective for this type of tumor.

According to Acting Director of the Department of Hematology and Oncology of the FDA, Richard Pazdur, this step is important for the cancer community. This is because the approval of treatments always took into consideration the region of the body where the tumor began, for example, lung or breast cancer. And now, a tumor biomarker-based drug has been approved regardless of the original location of the cancer.

Pembrolizumab has been approved for this new indication using the Accelerated Approval route under which the FDA can approve drugs for serious conditions in which the conventional medicines did not present a satisfactory result. Further studies are needed to describe the clinical benefits of a larger number of patients.


Is treatment safe?

Is treatment safe?

Not only must be evaluated the fold in the adipometer (an instrument by which the fat fold is measured in millimeters), but also, it is necessary to observe the manual fold, which evaluates the availability of skin for expansion of the fat located in the region to be treated, since without the elasticity of skin it is not possible that the suction generated by the apparatus happens safely and guarantees results.

(Health)

Anvisa approves new medicine for hepatitis C

Anvisa approves new medicine for hepatitis C

The National Agency of Sanitary Surveillance (Anvisa) approved the registration of a new medicine for the treatment of Hepatitis C. The approval was published in the Official Gazette (DOU) , according to Anvisa, Maviret (glecaprevir / pibrentasvir) will be marketed in the form of a coated tablet with a concentration of 100mg and 40mg.

(Health)